Cocrystal Pharma Stock Working Capital
| COCP Stock | USD 1.53 0.06 3.77% |
Cocrystal Pharma fundamentals help investors to digest information that contributes to Cocrystal Pharma's financial success or failures. It also enables traders to predict the movement of Cocrystal Stock. The fundamental analysis module provides a way to measure Cocrystal Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cocrystal Pharma stock.
Cocrystal |
Cocrystal Pharma Company Working Capital Analysis
Cocrystal Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Cocrystal Pharma Working Capital | 25.83 M |
Most of Cocrystal Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cocrystal Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Cocrystal Pharma has a Working Capital of 25.83 M. This is 93.93% lower than that of the Pharmaceuticals sector and 95.2% lower than that of the Health Care industry. The working capital for all United States stocks is 98.25% higher than that of the company.
Cocrystal Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cocrystal Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cocrystal Pharma could also be used in its relative valuation, which is a method of valuing Cocrystal Pharma by comparing valuation metrics of similar companies.Cocrystal Pharma is currently under evaluation in working capital category among its peers.
Cocrystal Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 4.42 M | ||||
| Shares Outstanding | 10.17 M | ||||
| Shares Owned By Insiders | 31.85 % | ||||
| Shares Owned By Institutions | 6.99 % | ||||
| Number Of Shares Shorted | 14.37 K | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 92.45 X | ||||
| Gross Profit | (14.77 M) | ||||
| EBITDA | (19.37 M) | ||||
| Net Income | (17.98 M) | ||||
| Cash And Equivalents | 51.03 M | ||||
| Cash Per Share | 6.28 X | ||||
| Total Debt | 1.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 18.34 X | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | (14.67 M) | ||||
| Short Ratio | 0.55 X | ||||
| Earnings Per Share | (1.84) X | ||||
| Target Price | 8.33 | ||||
| Number Of Employees | 12 | ||||
| Beta | 2.35 | ||||
| Market Capitalization | 15.57 M | ||||
| Total Asset | 31.26 M | ||||
| Retained Earnings | (315.91 M) | ||||
| Working Capital | 25.83 M | ||||
| Current Asset | 6.75 M | ||||
| Current Liabilities | 3.15 M | ||||
| Net Asset | 31.26 M |
About Cocrystal Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cocrystal Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cocrystal Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cocrystal Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.